Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease

Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease

Background and Aims. Thrombocytopenia is a common complication in patients with chronic hepatitis C virus (HCV) that increases the risk of bleeding. We aimed to analyze the hematologic effects of the new direct-acting antiviral (DAA) therapy, particularly on the platelet count in chronic HCV-infecte...

Full description

Bibliographic Details
Main Authors:	Mahmoud Saif-Al-Islam, Usama M. Abdelaal, Mustafa Adel Younis, Hisham A. Alghany Algahlan, Safaa Khalaf
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	Gastroenterology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2021/8811203

Similar Items

Periventricular Hemorrhage in Term and Late Preterm Neonates: Risk Factors and Outcomes
by: Ashraf Abou-Taleb, et al.
Published: (2019-06-01)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
by: Chung Sang Tse, et al.
Published: (2021-01-01)

Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease
by: Woo Jin Chung
Published: (2016-01-01)

Association of direct-acting antiviral therapy for hepatitis C with the development and recurrence of liver cancer
by: LI Yan
Published: (2018-02-01)

Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
by: Yen-Chun Chen, et al.
Published: (2021-01-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01)

Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients
by: Shimaa Kamel, et al.
Published: (2021-07-01)

The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals
by: Fayed HM, et al.
Published: (2020-02-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Mexican experience with direct-acting antivirals in the treatment of hepatitis C
by: J.L. Pérez Hernández, et al.
Published: (2020-09-01)

Treatment of hepatitis C using direct-acting antiviral (DAA) agents in patients undergoing liver transplantation
by: V. E. Syutkin, et al.
Published: (2016-02-01)

Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
by: Myung Hee Kim, et al.
Published: (2020-02-01)

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
by: Omar A. Saldarriaga, et al.
Published: (2021-07-01)

THE EVOLUTION OF LIVER FIBROSIS AFTER THE TREATMENT WITH DIRECT-ACTING ANTIVIRAL AGENTS IN HEPATIC CIRRHOSIS: EXPERIENCE OF A CENTER
by: Mariana Avricenco, et al.
Published: (2020-10-01)

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis
by: Ki Tae Yoon
Published: (2016-10-01)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
by: Tag-Adeen M, et al.
Published: (2017-10-01)

Clinical efficacy of direct-acting antiviral agents in treatment of patients with hepatitis C recurrence after liver transplantation
by: LIU Hongling, et al.
Published: (2015-12-01)

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
by: Jennifer Wellington, et al.
Published: (2021-09-01)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018-04-01)

Hepatitis C virus, directly acting antivirals and Guillain-Barré syndrome
by: Manish Balwani, et al.
Published: (2018-01-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
by: Eric R. Yoo, et al.
Published: (2016-01-01)

Discovery and evaluation of direct acting antivirals against hepatitis C virus
by: Abdurakhmanov, Eldar
Published: (2015)

Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals
by: Alexandre Pariente, et al.
Published: (2019-01-01)

The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma
by: Paulina Chinchilla-López, et al.
Published: (2017-05-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection
by: Ahmad M. Zidan, et al.
Published: (2021-05-01)

Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort
by: Maria Giovanna Quaranta, et al.
Published: (2021-05-01)

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.
by: Iria Rodríguez-Osorio, et al.
Published: (2019-01-01)

Status of liver stiffness following directly acting antiviral treatment in patients with chronic hepatitis C: A Nepalese study
by: Dilip Sharma, et al.
Published: (2017-10-01)

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals
by: Nițescu Maria, et al.
Published: (2017-10-01)

Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers
by: Chun-Han Cheng, et al.
Published: (2021-05-01)

SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection
by: Abdullah S Alghamdi, et al.
Published: (2015-01-01)

Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C
by: Maureen Whitsett, et al.
Published: (2019-06-01)

Real-World Results of Direct-Acting Antiviral Agents for Chronic Hepatitis C
by: Chun-Ming Hong, et al.
Published: (2018)

Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
by: Wei-Chen Lin, et al.
Published: (2020-01-01)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
by: Marta Gallach, et al.
Published: (2018-01-01)

Therapeutic vaccines against the hepatitis C virus in the age of direct-acting antivirals
by: Zaily Dorta-Guridi, et al.

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)